MarketPulse

psoriatic arthritis

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Moonlake Immunotherapeutics

MoonLake's Sonelokimab Sustains Strong Phase 3 Results in Hidradenitis Suppurativa

MoonLake reports Week 40 Phase 3 data for sonelokimab showing 62% HiSCR75 response rates in hidradenitis suppurativa with no new safety signals.
MLTXPhase 3 clinical trialquality of life
GlobeNewswire Inc.GlobeNewswire Inc.··Spherix Global Insights

Rheumatologists Split on Sotyktu's Market Impact Ahead of FDA Decision

BMS's Sotyktu shows promise for psoriatic arthritis among one-third of surveyed rheumatologists, but analysts expect modest market capture ahead of March 2026 FDA decision.
AMGNBMYCELGrJNJPFE+1psoriatic arthritisTYK2 inhibitor